Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy

Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline ha...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiology 2010-03, Vol.55 (2), p.174-179
Hauptverfasser: Kinbara, Terufumi, MD, Hayano, Tomoko, MD, Ohtani, Nozomu, MD, Furutani, Yuhji, MD, Moritani, Kohshiro, MD, Matsuzaki, Masunori, MD, FJCC
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 179
container_issue 2
container_start_page 174
container_title Journal of cardiology
container_volume 55
creator Kinbara, Terufumi, MD
Hayano, Tomoko, MD
Ohtani, Nozomu, MD
Furutani, Yuhji, MD
Moritani, Kohshiro, MD
Matsuzaki, Masunori, MD, FJCC
description Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.
doi_str_mv 10.1016/j.jjcc.2009.10.006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_748991220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0914508709002809</els_id><sourcerecordid>748991220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</originalsourceid><addsrcrecordid>eNp9kU-L1TAUxYMoznOcL-BCunPV502aNg2IIMP4BwZdqItZhcztrS-1L6lJO9Bvb8obXcxiyCLhcM6B_A5jrzjsOfDm7bAfBsS9ANBZ2AM0T9iOt6opparap2wHmsuyhladsRcpDdkAum2eszMBIr8bvWM3V33v0OJahL74WlqkeR1xTTM5T4X1XWGPzofpsI7jpjhfTJHuyM_O_yow-DnaNJfOdwtSV3iaDjFMdj6sL9mz3o6JLu7vc_bz49WPy8_l9bdPXy4_XJdYq2ouK95ywApqpWspZFfJXkmSNYJs8RZ5nY-qesEtr3viFhBED8gFb5TlBNU5e3PqnWL4s1CazdElpHG0nsKSjJKt1lyIzSlOTowhpUi9maI72rgaDmYjagazETUb0U3LwHLo9X39cnuk7n_kH8JseHcyUP7knaNoEjrymYaLhLPpgnu8__2DOGbQeZLxN62UhrBEn_EZbpIwYL5vm26TggYQLejqL6Z3m_4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>748991220</pqid></control><display><type>article</type><title>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kinbara, Terufumi, MD ; Hayano, Tomoko, MD ; Ohtani, Nozomu, MD ; Furutani, Yuhji, MD ; Moritani, Kohshiro, MD ; Matsuzaki, Masunori, MD, FJCC</creator><creatorcontrib>Kinbara, Terufumi, MD ; Hayano, Tomoko, MD ; Ohtani, Nozomu, MD ; Furutani, Yuhji, MD ; Moritani, Kohshiro, MD ; Matsuzaki, Masunori, MD, FJCC</creatorcontrib><description><![CDATA[Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.]]></description><identifier>ISSN: 0914-5087</identifier><identifier>EISSN: 1876-4738</identifier><identifier>DOI: 10.1016/j.jjcc.2009.10.006</identifier><identifier>PMID: 20206069</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acetylcysteine - administration &amp; dosage ; Acetylcysteine - therapeutic use ; Aged ; Aminophylline ; Aminophylline - administration &amp; dosage ; Aminophylline - therapeutic use ; Angioplasty, Balloon, Coronary - adverse effects ; beta 2-Microglobulin - blood ; beta 2-Microglobulin - urine ; Cardiovascular ; Contrast Media - adverse effects ; Contrast-induced nephropathy ; Coronary Angiography - adverse effects ; Creatinine - blood ; Creatinine - metabolism ; Female ; Humans ; Kidney Diseases - chemically induced ; Kidney Diseases - prevention &amp; control ; Male ; N-acetylcysteine ; Renal function</subject><ispartof>Journal of cardiology, 2010-03, Vol.55 (2), p.174-179</ispartof><rights>Japanese College of Cardiology</rights><rights>2009 Japanese College of Cardiology</rights><rights>Copyright 2009 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</citedby><cites>FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0914508709002809$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20206069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kinbara, Terufumi, MD</creatorcontrib><creatorcontrib>Hayano, Tomoko, MD</creatorcontrib><creatorcontrib>Ohtani, Nozomu, MD</creatorcontrib><creatorcontrib>Furutani, Yuhji, MD</creatorcontrib><creatorcontrib>Moritani, Kohshiro, MD</creatorcontrib><creatorcontrib>Matsuzaki, Masunori, MD, FJCC</creatorcontrib><title>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</title><title>Journal of cardiology</title><addtitle>J Cardiol</addtitle><description><![CDATA[Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.]]></description><subject>Acetylcysteine - administration &amp; dosage</subject><subject>Acetylcysteine - therapeutic use</subject><subject>Aged</subject><subject>Aminophylline</subject><subject>Aminophylline - administration &amp; dosage</subject><subject>Aminophylline - therapeutic use</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>beta 2-Microglobulin - blood</subject><subject>beta 2-Microglobulin - urine</subject><subject>Cardiovascular</subject><subject>Contrast Media - adverse effects</subject><subject>Contrast-induced nephropathy</subject><subject>Coronary Angiography - adverse effects</subject><subject>Creatinine - blood</subject><subject>Creatinine - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Diseases - chemically induced</subject><subject>Kidney Diseases - prevention &amp; control</subject><subject>Male</subject><subject>N-acetylcysteine</subject><subject>Renal function</subject><issn>0914-5087</issn><issn>1876-4738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-L1TAUxYMoznOcL-BCunPV502aNg2IIMP4BwZdqItZhcztrS-1L6lJO9Bvb8obXcxiyCLhcM6B_A5jrzjsOfDm7bAfBsS9ANBZ2AM0T9iOt6opparap2wHmsuyhladsRcpDdkAum2eszMBIr8bvWM3V33v0OJahL74WlqkeR1xTTM5T4X1XWGPzofpsI7jpjhfTJHuyM_O_yow-DnaNJfOdwtSV3iaDjFMdj6sL9mz3o6JLu7vc_bz49WPy8_l9bdPXy4_XJdYq2ouK95ywApqpWspZFfJXkmSNYJs8RZ5nY-qesEtr3viFhBED8gFb5TlBNU5e3PqnWL4s1CazdElpHG0nsKSjJKt1lyIzSlOTowhpUi9maI72rgaDmYjagazETUb0U3LwHLo9X39cnuk7n_kH8JseHcyUP7knaNoEjrymYaLhLPpgnu8__2DOGbQeZLxN62UhrBEn_EZbpIwYL5vm26TggYQLejqL6Z3m_4</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Kinbara, Terufumi, MD</creator><creator>Hayano, Tomoko, MD</creator><creator>Ohtani, Nozomu, MD</creator><creator>Furutani, Yuhji, MD</creator><creator>Moritani, Kohshiro, MD</creator><creator>Matsuzaki, Masunori, MD, FJCC</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</title><author>Kinbara, Terufumi, MD ; Hayano, Tomoko, MD ; Ohtani, Nozomu, MD ; Furutani, Yuhji, MD ; Moritani, Kohshiro, MD ; Matsuzaki, Masunori, MD, FJCC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acetylcysteine - administration &amp; dosage</topic><topic>Acetylcysteine - therapeutic use</topic><topic>Aged</topic><topic>Aminophylline</topic><topic>Aminophylline - administration &amp; dosage</topic><topic>Aminophylline - therapeutic use</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>beta 2-Microglobulin - blood</topic><topic>beta 2-Microglobulin - urine</topic><topic>Cardiovascular</topic><topic>Contrast Media - adverse effects</topic><topic>Contrast-induced nephropathy</topic><topic>Coronary Angiography - adverse effects</topic><topic>Creatinine - blood</topic><topic>Creatinine - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Diseases - chemically induced</topic><topic>Kidney Diseases - prevention &amp; control</topic><topic>Male</topic><topic>N-acetylcysteine</topic><topic>Renal function</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kinbara, Terufumi, MD</creatorcontrib><creatorcontrib>Hayano, Tomoko, MD</creatorcontrib><creatorcontrib>Ohtani, Nozomu, MD</creatorcontrib><creatorcontrib>Furutani, Yuhji, MD</creatorcontrib><creatorcontrib>Moritani, Kohshiro, MD</creatorcontrib><creatorcontrib>Matsuzaki, Masunori, MD, FJCC</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kinbara, Terufumi, MD</au><au>Hayano, Tomoko, MD</au><au>Ohtani, Nozomu, MD</au><au>Furutani, Yuhji, MD</au><au>Moritani, Kohshiro, MD</au><au>Matsuzaki, Masunori, MD, FJCC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</atitle><jtitle>Journal of cardiology</jtitle><addtitle>J Cardiol</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>55</volume><issue>2</issue><spage>174</spage><epage>179</epage><pages>174-179</pages><issn>0914-5087</issn><eissn>1876-4738</eissn><abstract><![CDATA[Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.]]></abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>20206069</pmid><doi>10.1016/j.jjcc.2009.10.006</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0914-5087
ispartof Journal of cardiology, 2010-03, Vol.55 (2), p.174-179
issn 0914-5087
1876-4738
language eng
recordid cdi_proquest_miscellaneous_748991220
source MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Acetylcysteine - administration & dosage
Acetylcysteine - therapeutic use
Aged
Aminophylline
Aminophylline - administration & dosage
Aminophylline - therapeutic use
Angioplasty, Balloon, Coronary - adverse effects
beta 2-Microglobulin - blood
beta 2-Microglobulin - urine
Cardiovascular
Contrast Media - adverse effects
Contrast-induced nephropathy
Coronary Angiography - adverse effects
Creatinine - blood
Creatinine - metabolism
Female
Humans
Kidney Diseases - chemically induced
Kidney Diseases - prevention & control
Male
N-acetylcysteine
Renal function
title Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A32%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20N-acetylcysteine%20and%20aminophylline%20in%20preventing%20contrast-induced%20nephropathy&rft.jtitle=Journal%20of%20cardiology&rft.au=Kinbara,%20Terufumi,%20MD&rft.date=2010-03-01&rft.volume=55&rft.issue=2&rft.spage=174&rft.epage=179&rft.pages=174-179&rft.issn=0914-5087&rft.eissn=1876-4738&rft_id=info:doi/10.1016/j.jjcc.2009.10.006&rft_dat=%3Cproquest_cross%3E748991220%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=748991220&rft_id=info:pmid/20206069&rft_els_id=1_s2_0_S0914508709002809&rfr_iscdi=true